Company
Every investor coverage indicates participated in a round Diabetes Australia raised.
Companies Diabetes Australia acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Diabetes Australia. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech ImmunoBiota courts investors for its still-open seed round around an oral Type 1 diabetes therapy; its recent Diabetes Australia award is recorded, while the flagged Series A and listing remain plans.
Melbourne biotech ImmunoBiota Therapeutics, a Monash University spinout, is developing an oral type 1 diabetes treatment and seeking seed funding for paediatric trials; its founder won a Diabetes Australia innovation prize.